1-Tert-Butyl 2-Methyl (2R)-4-Oxopyrrolidine-1,2-Dicarboxylate

In the large-scale synthesis of macrocyclic HCV NS3/4A serine protease inhibitors, the chiral (R)-configured pyrrolidinone diester functions as the non-proteinogenic P2 proline surrogate. The manufacturing process initiates with the coupling of 1-tert-butyl 2-methyl (2R)-4-oxopyrrolidine-1,2-dicarboxylate to a P1–P3 peptide backbone fragment, typically dissolved in anhydrous N,N-dimethylformamide held at -15 °C to -5 °C. A combination of 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) and N,N-diisopropylethylamine ensures activation with minimal epimerization at the Cα position—a documented failure mode when the internal reaction temperature exceeds +2 °C, at which point the undesired S-epimer can rise from a baseline of <0.3% to >1.8% as quantified by Chiralpak IG-3 column (USP <621>) using a n-hexane/ethanol/diethylamine mobile phase. The active ester intermediate is subjected to a Pd-mediated hydrogenolysis in a Hastelloy C-22 autoclave at 0.3–0.5 MPa hydrogen pressure and 25 °C for 6–8 hours to remove a Cbz masking group, followed by macrocyclization with HATU in dilute toluene (0.008–0.012 M). After transfer to a glass-lined Büchi reactor, the tert-butyl carbamate is cleaved with anhydrous hydrochloric acid in cyclopentyl methyl ether at 10–15 °C; residual water above 500 ppm (Karl Fischer per ASTM E203-16) triggers premature deprotection and gumming on the agitator shaft. The final API—usually obtained as a dimesylate or dihydrochloride salt via acetonitrile/water recrystallization with seeded cooling rates of 0.3 °C/min—is dried in a double-cone vacuum dryer (40 °C, ≤10 mbar) until loss on drying is ≤0.5%. Regulatory oversight follows ICH Q7 GMP for active pharmaceutical ingredients and 21 CFR 210–211; the starting material is registered under a Type II Drug Master File with a specification including assay (≥99.0% area by HPLC), enantiomeric excess (≥99.5%), and residual solvents controlled per USP <467> Method IV. The molar charging ratio of the diester to the peptide fragment is maintained at 0.98–1.05 equiv; excursions above 1.08 equiv result in a difficult-to-purge dimeric impurity that co-elutes with the product during preparative silica gel chromatography. The ultimate dosage form is typically an immediate-release film-coated tablet of 100–150 mg API strength, packaged in alu-alu blisters with an integrated silica gel desiccant pocket.

What Limits the Epimerization Rate During Amide Bond Formation in Proline-Derived Building Blocks?

When the (2R)-4-oxopyrrolidine-1,2-dicarboxylate scaffold is deployed in the assembly of orally bioavailable Factor Xa inhibitors, the kinetic vulnerability resides in the acidity of the C2 methine proton adjacent to the methyl ester. In a typical route, the diester undergoes regioselective sodium borohydride reduction of the ketone at -20 °C in methanol, after which the resulting alcohol is activated as a mesylate and displaced with a 4-aminopiperidine-derived fragment. The addition ratio of the piperidine nucleophile must be controlled to 1.00–1.03 molar equivalent relative to the mesylate; using ≥1.07 equiv leads to detectable dimerisation via intermolecular attack on the methyl ester, a by-product identified through UPLC-QTOF (Waters Acquity H-Class coupled to Xevo G2-XS) with a mass accuracy of <3 ppm. The subsequent amide coupling with a chloro-thiophene carboxamide entity uses propanephosphonic acid anhydride (T3P, 50 wt% in ethyl acetate) at 0–5 °C, buffered with pyridine to maintain the apparent pH between 5.8 and 6.2. Epimerization monitoring performed via a Chiral Technologies Chiralpak AD-H column (test method derived from DIN 38407-14 principles) shows that exceeding 8 hours of post-reaction stirring at this pH window raises the D-allo-isomer content to 0.35–0.40%, above the 0.15% acceptable threshold specified in the active pharmaceutical ingredient master file. Compliance with ICH M7(R2) for mutagenic impurities requires dedicated purge factor calculations for the mesylation step; the methyl methanesulfonate formed is quenched with aqueous ammonia and monitored by headspace GC-MS (Agilent 7697A/5977B) to a level of <1 µg/g. Process equipment employed includes a Pfaudler BA series glass-lined reactor with retreat-curve impeller, operated at a tip speed of 3.0 m/s to prevent vortex-induced enantiomer gradient formation during work-up. Terminal deprotection of the tert-butyl group is performed with trifluoroacetic acid/triisopropylsilane (95:5 v/v) in dichloromethane at 20 °C; the crude free carboxylic acid is converted to the sodium salt and freeze-dried (Virtis Genesis SQ freeze-dryer) to yield the sterile active ingredient. The final product is formulated as a lyophilized powder for injection (50 mg per vial), reconstituted in sterile water for injection immediately before administration, and must meet USP <71> sterility and USP <85> bacterial endotoxin limits. This entire route is operated under a Quality Management System certified to ISO 9001:2015 and consistent with EU REACH Regulation (EC) No 1907/2006, with the diester pre-registered for a tonnage band of 1–10 tonnes per annum.

When the methyl ester serves as a latent carboxyl protecting group in the manufacturing of DPP-4 inhibitors, the intermediate participates in a Knoevenagel-type condensation with a 2-cyano-3-substituted-phenyl acrylate partner. The chiral diester is first converted to an aldehyde via a two-step procedure: controlled reduction with DIBAL-H at -78 °C in toluene (0.5 M, 1.02 equiv) to the corresponding aldehyde followed by immediate use without isolation; the half-life of this aldehyde in the presence of trace triethylamine is less than 40 minutes at 25 °C. During the subsequent tandem Michael addition-cyclisation cascade, the stoichiometry of the diester-derived aldehyde relative to the cyanoester is held at precisely 1.00:1.00 eq, because even a 2% molar excess of the aldehyde results in the formation of a fluorescent dimer that accounts for 0.6–0.9% of the total peak area in the API crude, necessitating an additional silica plug filtration step. The crude cyclised product is submitted to a lipase-mediated kinetic resolution using Candida antarctica lipase B immobilized on acrylic resin (Novozym 435) in a methyl tert-butyl ether/water biphasic system at 35 °C; the (2R)-center installed in the starting diester directs the enzyme to selectively hydrolyse the desired stereoisomer, leaving the off-enantiomer intact. The aqueous phase is acidified to pH 3.0 with phosphoric acid and extracted, and the carboxylic acid is crystallised from isopropyl acetate/n-heptane (1:5 v/v) with a yield of 72–78% after vacuum drying (Heidolph Rotary Evaporator Hei-VAP Expert, 40 °C/10 mbar). Residual acetonitrile and MTBE are controlled at ≤310 ppm and ≤8 ppm respectively through online near-infrared spectroscopy (Bruker MATRIX-F) verification, in accordance with USP <467> Option 1. The isolated enantiopure acid is then subjected to HATU-mediated amidation with a cis-2,5-diazabicyclo[2.2.2]octane dihydrochloride fragment to furnish the penultimate intermediate. The entire reaction sequence is executed in a Kilolab glide-scale reactor (Radleys Reactor Ready Pilot) under nitrogen, with the jacketed vessel temperature stability of ±0.5 °C. The final active pharmaceutical ingredient is micronized (Jet-O-Mizer jet mill, nitrogen pressure 8 bar) and filled into hard gelatin capsules at a dose strength of 25 mg and 100 mg; dissolution testing per USP <711> App. II shows >85% release in 30 min at pH 1.2.

When Ketoproline Methyl Ester Intervenes in Constructing ATP-Competitive Kinase Hinge Binders

In the synthesis route toward certain macrocyclic tyrosine kinase inhibitors that occupy the hinge region via a pyrrolidinone-carbonyl hydrogen bond, the (2R)-4-oxopyrrolidine-1,2-dicarboxylate scaffold provides the preconfigured (R)-geometry necessary for complementarity with the gatekeeper residue. The diester is converted into a 2-aminopyrimidine-linked hybrid through a Buchwald–Hartwig amination between the lactam nitrogen (after iPrMgCl·LiCl-mediated deprotonation at -30 °C) and a 5-bromo-2-chloropyrimidine. The palladium precatalyst XPhos Pd G3 is charged at 1.5 mol% relative to the bromide, and the reaction is run in 2-methyltetrahydrofuran at 45±2 °C for 18 h. The molar ratio of the diester to the bromopyrimidine must be maintained at 1.00:1.05—the slight excess of the electrophile prevents the formation of a doubly arylated impurity that co-crystallizes with the product in the subsequent toluene/heptane crystallization. Underpinning the process is the compliance with the European Pharmacopoeia general monograph 2034 (Substances for Pharmaceutical Use), with additional monitoring for Class 1 heavy metals by ICP-OES (PerkinElmer Avio 550 Max) as per EN 71-3:2019 adapted for chemical substrates. Process experience on a 50 L scale reveals that oxygen levels must be reduced below 500 ppm in the headspace; a single sparge failure caused Pd black precipitation and a 5.2% loss of batch that required Celtie filtration and rework. After the cross-coupling, the methyl ester is saponified with lithium hydroxide monohydrate (1.15 eq) in THF/water (4:1) at 10 °C over 3 h, a protocol that avoids the 0.5–0.7% α-racemization observed when sodium hydroxide is used at the same pH. The carboxylic acid is then attached to a 4-(4-methylpiperazin-1-yl)piperidine segment via mixed anhydride methodology (isobutyl chloroformate, N-methylmorpholine, -5 °C) and subsequently subjected to ring-closing metathesis with a Grubbs 2nd generation catalyst (3 mol%) in degassed dichloromethane at 40 °C. The formed macrocycle is hydrogenated over 10% Pd/C in a HEL AutoLAB reactor, and residual ruthenium is scavenged with QuadraSil AP (3 wt%) to below 10 ppm per ICH Q3D Elemental Impurity guidelines. The final API is crystallized from ethyl acetate as the anhydrous free base, passing DSC (Mettler Toledo DSC 3+) and TGA (Mettler Toledo TGA 2) specifications; it is subsequently formulated with lactose monohydrate and croscarmellose sodium into immediate-release tablets of 40 mg strength, blister-sealed under nitrogen. The manufacturing facility operates under EU GMP Part II for API and holds a valid CEP (Certificate of Suitability to the Monographs of the European Pharmacopoeia).

Alternatively, the enantiopure building block finds application in the preparation of conformationally constrained peptidomimetics that exploit the ketone group for oxime ligation in solid-phase peptide synthesis. The (2R)-4-oxopyrrolidine-1,2-dicarboxylate is first treated with solid NH₂-NH-Boc in methanol to form an hydrazone, which under acetylacetone/HCl conditions cyclizes to a pyrazole-fused proline analogue. The downstream manufacturing process relies on a precise stoichiometric control: addition of 0.95–0.98 mmol of the diester per gram of preloaded 2-chlorotrityl chloride resin (substitution 0.8 mmol/g) in CH₂Cl₂/DMF (3:1) with DIEA (4.0 eq). Lower loadings result in incomplete capping, while higher loads cause inter-strand crosslinking detectable by a decrease in swelling volume by 11–15%. Each coupling step after the scaffold immobilisation utilizes Fmoc-Xaa-OH activated with PyOxP and DIPEA in an automated peptide synthesizer (CS Bio CS336X), with ninhydrin monitoring ensuring ≥99.3% coupling efficiency. The peptidomimetic is cleaved with TFA/TIS/H₂O (95:2.5:2.5) for 2.5 h and precipitated in cold diethyl ether. Preparative reversed-phase HPLC (Waters AutoPurification with XBridge BEH C18 OBD column, 5 µm, 150 x 30 mm) isolates the target peptide with a typical purity of ≥98.5%. Analytical characterization follows the current version of USP <791> for chromatographic procedures. The final product type is a lyophilized peptide (> 95% purity by HPLC) supplied in glass vials under argon as a research-grade tool for preclinical screening, accompanied by a Certificate of Analysis referencing DIN EN ISO/IEC 17025 for competence of testing and calibration laboratories. The entire small-scale supply chain is compliant with ECHA registration for R&D-limited quantities (exempted from full tonnage registration) and OSHA HCS 2012 for hazard communication.

Pyrrolidinone Diester Utility in Factor Xa Inhibitor Process Chemistry

When deployed as the chiral pool entry into pyrazolo[3,4-c]pyridine-based Factor Xa inhibitors, the diester undergoes a high-yielding thermal Dieckmann-type condensation with diethyl oxalate in the presence of sodium ethoxide (2.2 eq) in refluxing ethanol. The addition proportion of the diester to sodium ethoxide is held at 1.00:2.20, as a substoichiometric base quantity (<2.0 eq) triggers incomplete enolate formation and leads to a 15–20% reduction in isolated yield due to dimerization of the pyrrolidinone. The resulting 3-ethoxycarbonyl intermediate is treated with a substituted hydrazine hydrate in acetic acid at 95 °C for 5 h to construct the fused pyrazole core. Process robustness is attested through Design of Experiments (DoE) evaluations on a Easymax 402 Advanced Reactor (Mettler Toledo) with online FTIR monitoring (ReactIR 15) of the lactam carbonyl shift at 1750 cm^-1; a reaction temperature overshoot to 105 °C in one validation batch caused ring-opening of the oxazolidinone protective group and introduced a 1.1% cross-contaminant. This step is conducted strictly under GHS hazard classification and operates within an emission-controlled enclosure (HARDI International spray cabinet) due to the hydrazine moiety. The chloropyridine coupling partner is then appended via a Negishi cross-coupling using PdCl₂(dppf)·CH₂Cl₂ (1.8 mol%) at 65 °C in THF, with residual zinc monitored by inductively coupled plasma mass spectrometry (Agilent 7900 ICP-MS) to meet the ICH Q3D limit for zinc (≤1300 µg/day). The methyl ester is retained through all synthetic steps and hydrolyzed with sulphuric acid (2.0 M, 80 °C, 4 h) immediately prior to final salt formation with tromethamine in ethanol. The tromethamine salt of the API—marketed as an intravenous bolus formulation of 10 mg/mL—must be sterile-filtered through a 0.2 µm PVDF membrane (Millipore Express SHF) and meet USP <788> Particulate Matter standards. The entire process is validated according to ICH Q2(R2) on analytical procedures, and the site has passed inspections under EU GMP Annex 15 qualification and validation.